PUBLIC COMPANY
save$ARWRARROWHEAD PHARMACEUTICALS, INC.
$ARWR87.47-2.17%Pasadena, CA, USupdated 5h ago
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
community read0 votes
pipeline
4
marketed
1
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
1Phase 21Phase 31Marketed1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
- phase1A First-In-Human Study of ARO-033 in Adult Participants
- phase3A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
- phase3Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
- phase2A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
- phase2Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
- phase2Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
- phase2Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 23, 26SELLHamilton James C· Chief Medical Officer−$750K↗
- Apr 22, 26SELLApel Daniel Joseph· Chief Financial Officer−$628K↗
- Apr 22, 26SELLApel Daniel Joseph· Chief Financial Officer−$225K↗
- Apr 22, 26SELLApel Daniel Joseph· Chief Financial Officer−$82K↗
- Mar 5, 26SELLHamilton James C· Chief Medical Officer−$642K↗
🐶 Hiring Signal
News
- Epicrispr lands $90M to advance epigenetic editing drug for rare muscle diseaseThe startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.biopharma_dive · 9d ago
- ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culpritEarly indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.biopharma_dive · 13d ago
- Biotechs bring big launches and pharma rivalries into Q2 earnings periodWith the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.biospace · 22d ago
- Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drugWith Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follo…biospace · 29d ago
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that